文献速递肝胆胰外科围术期管理与 ERAS

手术时机与临床I-II期胰腺腺癌 upfront手术结局的关联

Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery.
PubMed 文献 · Surgery · 2017-12-13

基于2004-2012年美国国家癌症数据库回顾性分析16763例接受upfront手术的临床I-II期胰腺导管腺癌患者,按手术等待时间分为短(1-14天,34.4%)、中(15-42天,51.6%)、长(43-120天,14.0%)三组。中、长等待组较短期组总生存改善(HR分别为0.94和0.91),90天死亡率更低,且肿瘤学次要结局无差异。

要点

  • 手术等待15-42天或43-120天与更优总生存相关,短等待(1-14天)生存略差。
  • 中、长等待组90天死亡率低于短等待组,围术期安全性更好。
  • 等待时间不影响淋巴结阳性率、病理升级、不可切除率或切缘阳性率。

核心结论

  • 在可切除胰腺导管腺癌upfront手术患者中,短手术等待时间与略短的总生存和更高的围术期死亡率相关。
  • 结果提示为医学优化和转诊至高容量外科医生而延迟手术可能是安全的。

研究设计与样本

  • 回顾性观察性分析,使用2004-2012年美国国家癌症数据库。
  • 纳入16763例接受治愈性意向手术、未行新辅助治疗的临床I-II期胰腺导管腺癌患者。
  • 采用限制性立方样条Cox模型定义手术等待时间分组:短(1-14天)、中(15-42天)、长(43-120天)。
  • 总生存采用Cox共享脆弱模型分析,次要结局采用混合效应逻辑回归模型。

主要发现

  • 手术等待时间分布:短34.4%,中51.6%,长14.0%。
  • 短等待组更多为年轻、有私人保险、健康状态好、在低容量医院治疗的患者。
  • 淋巴结阳性、临床至病理升级、探查时不可切除或IV期、切缘阳性的调整比值比无差异。
  • 中等待组接受充分淋巴结清扫的调整比值比高于短等待组(OR 1.11,95%CI 1.03-1.20)。

临床怎么用

  • 对于可切除胰腺导管腺癌拟行upfront手术者,不应因担心肿瘤进展而排斥必要的术前医学优化和转诊。
  • 短等待(1-14天)并非优势,可考虑将手术安排在15-42天或更长以改善围术期结局。

局限性

  • 为观察性回顾性分析,可能存在未测量混杂。
  • 使用国家癌症数据库,手术等待时间分组基于统计模型定义,非预设临床阈值。
  • 未纳入接受新辅助治疗的患者,结论仅适用于upfront手术人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Time-to-surgery from cancer diagnosis has increased in the United States. We aimed to determine the association between time-to-surgery and oncologic outcomes in patients with resectable pancreatic ductal adenocarcinoma undergoing upfront surgery. METHODS: The 2004-2012 National Cancer Database was reviewed for patients undergoing curative-intent surgery without neoadjuvant therapy for clinical stage I-II pancreatic ductal adenocarcinoma. A multivariable Cox model with restricted cubic splines was used to define time-to-surgery as short (1-14 days), medium (15-42), and long (43-120). Overall survival was examined using Cox shared frailty models. Secondary outcomes were examined using mixed-effects logistic regression models. RESULTS: Of 16,763 patients, time-to-surgery was short in 34.4%, medium in 51.6%, and long in 14.0%. More short time-to-surgery patients were young, privately insured, healthy, and treated at low-volume hospitals. Adjusted hazards of mortality were lower for medium (hazard ratio 0.94, 95% confidence interval, .90, 0.97) and long time-to-surgery (hazard ratio 0.91, 95% confidence interval, 0.86, 0.96) than short. There were no differences in adjusted odds of node positivity, clinical to pathologic upstaging, being unresectable or stage IV at exploration, and positive margins. Medium time-to-surgery patients had higher adjusted odds (odds ratio 1.11, 95% confidence interval, 1.03, 1.20) of receiving an adequate lymphadenectomy than short. Ninety-day mortality was lower in medium (odds ratio 0.75, 95% confidence interval, 0.65, 0.85) and long time-to-surgery (odds ratio 0.72, 95% confidence interval, 0.60, 0.88) than short. CONCLUSION: In this observational analysis, short time-to-surgery was associated with slightly shorter OS and higher perioperative mortality. These results may suggest that delays for medical optimization and referral to high volume surgeons are safe.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Swords DS, Zhang C, Presson AP, et al. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Surgery. 2017. PMID: 29248179. doi:10.1016/j.surg.2017.10.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。